Synthetic lethality in lung cancer and translation to clinical therapies
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Synthetic lethality in lung cancer and translation to clinical therapies
Authors
Keywords
Lung cancer, Synthetic lethality, Combination treatments, Synergy, Drug-drug interactions
Journal
Molecular Cancer
Volume 15, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-09-29
DOI
10.1186/s12943-016-0546-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Drugging Undruggable Molecular Cancer Targets
- (2016) John S. Lazo et al. Annual Review of Pharmacology and Toxicology
- Recent advances in quantitative high throughput and high content data analysis
- (2016) Ioannis K. Moutsatsos et al. Expert Opinion on Drug Discovery
- shRNA-mediated AMBRA1 knockdown reduces the cisplatin-induced autophagy and sensitizes ovarian cancer cells to cisplatin
- (2016) Xiaoyan Li et al. JOURNAL OF TOXICOLOGICAL SCIENCES
- Advances, practice, and clinical perspectives in high-throughput sequencing
- (2016) S-J Park et al. ORAL DISEASES
- Synthetic lethal approaches for assessing combinatorial efficacy of chemotherapeutic drugs
- (2016) Rebecca A. Jackson et al. PHARMACOLOGY & THERAPEUTICS
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Combined Use of Gene Expression Modeling and siRNA Screening Identifies Genes and Pathways Which Enhance the Activity of Cisplatin When Added at No Effect Levels to Non-Small Cell Lung Cancer Cells In Vitro
- (2016) Ada W. Y. Leung et al. PLoS One
- CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
- (2016) Sara Costa-Cabral et al. PLoS One
- Emerging therapeutic drugs for AML
- (2015) E. M. Stein et al. BLOOD
- KRAS as a Therapeutic Target
- (2015) F. McCormick CLINICAL CANCER RESEARCH
- Peptide therapeutics: Targeting the undruggable space
- (2015) Natia Tsomaia EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer
- (2015) Robert Neijzen et al. JOURNAL OF CONTROLLED RELEASE
- CRISPR-Cas9 for medical genetic screens: applications and future perspectives
- (2015) Hui-Ying Xue et al. JOURNAL OF MEDICAL GENETICS
- Comprehensive genomic profiles of small cell lung cancer
- (2015) Julie George et al. NATURE
- Hitting cancers’ weak spots: vulnerabilities imposed by p53 mutation
- (2015) Evrim Gurpinar et al. TRENDS IN CELL BIOLOGY
- 3’-Phosphoadenosine 5’-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents
- (2015) Ada W. Y. Leung et al. Oncotarget
- NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer
- (2015) Collin M. Blakely et al. Cell Reports
- Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer
- (2015) Makoto Sudo et al. Oncotarget
- Doubling Down on the PI3K-AKT-mTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness
- (2015) Pradip De et al. NEOPLASIA
- Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening
- (2014) Zongxiang Zhou et al. BMC CANCER
- BRG1/SMARCA4 Inactivation Promotes Non-Small Cell Lung Cancer Aggressiveness by Altering Chromatin Organization
- (2014) T. Orvis et al. CANCER RESEARCH
- Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation
- (2014) B. G. Wilson et al. MOLECULAR AND CELLULAR BIOLOGY
- Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers
- (2014) G. R. Hoffman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MYCxing It Up with FGFR1 in Squamous Cell Lung Cancer
- (2014) W. Lockwood et al. Cancer Discovery
- Overall survival benefit for sequential doxorubicin–docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer—8-year results of the Breast International Group 02-98 phase III trial†
- (2013) C. Oakman et al. ANNALS OF ONCOLOGY
- Identification of potential synthetic lethal genes to p53 using a computational biology approach
- (2013) Xiaosheng Wang et al. BMC Medical Genomics
- Inference of synergy/antagonism between anticancer drugs from the pooled analysis of clinical trials
- (2013) Wenfeng Kang et al. BMC Medical Research Methodology
- LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug Phenformin
- (2013) David B. Shackelford et al. CANCER CELL
- ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status
- (2013) C. J. Huntoon et al. CANCER RESEARCH
- A Synthetic Lethality-Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1
- (2013) T. Oike et al. CANCER RESEARCH
- Topotecan and Doxorubicin Combination to Treat Recurrent Ovarian Cancer: The Influence of Drug Exposure Time and Delivery Systems to Achieve Optimum Therapeutic Activity
- (2013) N. A. Patankar et al. CLINICAL CANCER RESEARCH
- Knockdown of CABYR-a/b Increases Chemosensitivity of Human Non–Small Cell Lung Cancer Cells through Inactivation of Akt
- (2013) Zunlei Qian et al. MOLECULAR CANCER RESEARCH
- Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms
- (2013) J. Li et al. Molecular Systems Biology
- Treatment of Colorectal Cancer Using a Combination of Liposomal Irinotecan (Irinophore C™) and 5-Fluorouracil
- (2013) Jennifer I. Hare et al. PLoS One
- Proteasome Inhibitors Block DNA Repair and Radiosensitize Non-Small Cell Lung Cancer
- (2013) Kyle R. Cron et al. PLoS One
- Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers
- (2013) M. Pourdehnad et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genetic Screens in Human Cells Using the CRISPR-Cas9 System
- (2013) Tim Wang et al. SCIENCE
- Therapeutic Targeting of a Robust Non-Oncogene Addiction to PRKDC in ATM-Defective Tumors
- (2013) A. Riabinska et al. Science Translational Medicine
- MAX Inactivation in Small Cell Lung Cancer Disrupts MYC-SWI/SNF Programs and Is Synthetic Lethal with BRG1
- (2013) O. A. Romero et al. Cancer Discovery
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
- (2012) Ryan B. Corcoran et al. CANCER CELL
- Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition
- (2012) Matias Casás-Selves et al. CANCER RESEARCH
- The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer
- (2012) Madhu S. Kumar et al. CELL
- Targeting the DNA damage response in oncology
- (2012) Bristi Basu et al. CURRENT OPINION IN ONCOLOGY
- Passenger deletions generate therapeutic vulnerabilities in cancer
- (2012) Florian L. Muller et al. NATURE
- Divergent Genomic and Epigenomic Landscapes of Lung Cancer Subtypes Underscore the Selection of Different Oncogenic Pathways during Tumor Development
- (2012) William W. Lockwood et al. PLoS One
- Functional genomics identifies therapeutic targets for MYC-driven cancer
- (2012) M. Toyoshima et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability
- (2012) T. Luo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Searching for synthetic lethality in cancer
- (2011) Rachel Brough et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- New driver mutations in non-small-cell lung cancer
- (2011) William Pao et al. LANCET ONCOLOGY
- FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
- (2011) Trever G. Bivona et al. NATURE
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- (2011) Johannes Zuber et al. NATURE
- A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis
- (2011) J. D. Kessler et al. SCIENCE
- The p53 Pathway as a Target in Cancer Therapeutics: Obstacles and Promise
- (2011) A. Mandinova et al. Science Translational Medicine
- Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer
- (2010) Raj Chari et al. CANCER AND METASTASIS REVIEWS
- Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation
- (2010) Kenichi Suda et al. CANCER AND METASTASIS REVIEWS
- Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy
- (2010) James P. Sullivan et al. CANCER AND METASTASIS REVIEWS
- A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
- (2010) Marta Puyol et al. CANCER CELL
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Synthetic lethality: General principles, utility and detection using genetic screens in human cells
- (2010) Sebastian M.B. Nijman FEBS LETTERS
- RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells
- (2010) Shilpi Arora et al. GYNECOLOGIC ONCOLOGY
- Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models
- (2010) Silvestre Vicent et al. JOURNAL OF CLINICAL INVESTIGATION
- Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells
- (2010) Y Wang et al. ONCOGENE
- Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase
- (2010) D. Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
- (2009) Claudia Scholl et al. CELL
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
- (2009) Ji Luo et al. CELL
- Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors
- (2009) Ana M. Mendes-Pereira et al. EMBO Molecular Medicine
- Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo
- (2009) P. G. Tardi et al. MOLECULAR CANCER THERAPEUTICS
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
- (2009) David A. Barbie et al. NATURE
- Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application
- (2009) Aimee L. Jackson et al. NATURE REVIEWS DRUG DISCOVERY
- TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
- (2009) M. Olivier et al. Cold Spring Harbor Perspectives in Biology
- Identification of a Small Molecule with Synthetic Lethality for K-Ras and Protein Kinase C Iota
- (2008) W. Guo et al. CANCER RESEARCH
- The Yin and Yang of Treating BRCA-Deficient Tumors
- (2008) Richard W. Martin et al. CELL
- PTEN: a new guardian of the genome
- (2008) Y Yin et al. ONCOGENE
- Cisplatin: a review of toxicities and therapeutic applications
- (2008) K. Barabas et al. Veterinary and Comparative Oncology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started